Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial

PURPOSE: The aim of this study was to investigate whether external-beam accelerated partial-breast irradiation (APBI) provides noninferior local control compared with whole-breast irradiation (WBI). PATIENTS AND METHODS: We conducted this randomized phase III trial (ClinicalTrials.gov identifier: NCT01803958) in 35 centers. Patients age ≥49 years with invasive breast cancer, resection margins ≥2 mm, tumor diameter ≤3 cm, and pN0-1 were randomly assigned 1:1 to WBI or APBI (38.5 Gy in 10 fractions twice daily). Neither patients nor investigators were masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence (IBTR), analyzed according to the modified intention-to-treat analysis. We assumed a 5-year IBTR rate of 4% in the WBI group to exclude a 2% increase in the APBI group (90% power; noninferiority margin hazard ratio [HR], 1.5). RESULTS: Between 2007 and 2019, 3,309 patients were randomly assigned (1,652 to APBI, 1,657 to WBI); 84 were excluded from the analysis. The median follow-up was 97.5 months. The 5-year cumulative IBTR incidence was 1.0% (95% CI, 0.6 to 1.6) for APBI and 0.8% (95% CI, 0.5 to 1.4) for WBI. The HR for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20) with the upper confidence limit crossing the prespecified noninferiority margin. CONCLUSION: At 5 years, the cumulative incidence of IBTR is exceptionally low (≤1%) in both arms. Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%. External-beam APBI therefore is a reasonable clinical alternative to WBI for low-risk patients.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-11-17
DOI
https://doi.org/10.1200/jco-26-00969
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial

Dianne M. Busz, Nicola S. Russell, Cinzia Iotti, Antonino Romeo et al.
Journal of Clinical Oncology
Breast Cancer Treatment Studies
article

Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial

Dianne M. Busz, Nicola S. Russell, Cinzia Iotti, Antonino Romeo, Giovanna Benecchi, Daniela Patrizia Doino, Antoine M. Engelen, Alessandra Iannelli, Nunziata D’Abbiero, V. Vavassori, A. Baldissera, Anand Bhawanie, Liesbeth Jorinne Boersma, Paolo Rovea, Tonnis T. Nuver, Giovanna Mantello, Roberto D’Amico, Karolien Verhoeven, Barbara Sola, Marika C. Stenfert Kroese, Philip M. Poortmans, Gianpiero Catalano, Gabriele Guidi, Thomas Zilli, Erik C. Schimmel, Abraham Kuten, Liana Abdach, Antonella Richetti, Michele Troiano, Paul M. Jeene, Silvia Palazzi, Ilario Ammendolia, Mariacarla Valli, Shaniko Kaleci, Stefano Scicolone, Marleen Woltman-van Iersel, ALESSIO GIUSEPPE MORGANTI, Riccardo Cuoghi Costantini, Sara Ramella, Antonio Stefanelli, Eveline Koiter, Salvatore Roberto Bellia, Elisa D’Angelo, Marcel R. Stam, Luc J.E.E. Scheijmans, M. Cardinali, Anne P.G. Crijns, Hanneke J. M. Meijer, Gerda Wester, Francesca Cucciarelli, Letizia Fabbietti, Roberto Vicini, Gilles Ivaldi, Edy Ippolito, T.K.H. Eiland, Paolo Antognoni, Luciano Scandolaro, Michela Cassinotti, Paola Canino, Giovanni Tazzioli, Ilaria Meaglia, Salvatore Parisi, Frank Lohr, Tindara Munafò, G. Tolento, Anja Jonkman, Wout J. Schoevers, Bruno Meduri, Pietro Corsa, Maria Paola Ruggieri, Agostina De Stefani, Floranna Mauro, Selena Ciabatti, Patrizia Giacobazzi, A. González Sanchís, Giovanni Frezza, Filippo Bertoni, Carla Bianchi, Sabrina Cossa, Cristina Dell’Anna, Redona Tafili, John Maduro, Elena Zanella, Sandra Schildwacht, K. Muller, Filippo Grillo Ruggieri, Annalisa Venturini, Ellen Hendriksen, M.A.D. Haverkort, B. Kreike, P.G. Westhoff, El Jaouni Mohammad Khali, for the IRMA Trialists, Daniela Piva
article en

Abstract

PURPOSE: The aim of this study was to investigate whether external-beam accelerated partial-breast irradiation (APBI) provides noninferior local control compared with whole-breast irradiation (WBI). PATIENTS AND METHODS: We conducted this randomized phase III trial (ClinicalTrials.gov identifier: NCT01803958) in 35 centers. Patients age ≥49 years with invasive breast cancer, resection margins ≥2 mm, tumor diameter ≤3 cm, and pN0-1 were randomly assigned 1:1 to WBI or APBI (38.5 Gy in 10 fractions twice daily). Neither patients nor investigators were masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence (IBTR), analyzed according to the modified intention-to-treat analysis. We assumed a 5-year IBTR rate of 4% in the WBI group to exclude a 2% increase in the APBI group (90% power; noninferiority margin hazard ratio [HR], 1.5). RESULTS: Between 2007 and 2019, 3,309 patients were randomly assigned (1,652 to APBI, 1,657 to WBI); 84 were excluded from the analysis. The median follow-up was 97.5 months. The 5-year cumulative IBTR incidence was 1.0% (95% CI, 0.6 to 1.6) for APBI and 0.8% (95% CI, 0.5 to 1.4) for WBI. The HR for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20) with the upper confidence limit crossing the prespecified noninferiority margin. CONCLUSION: At 5 years, the cumulative incidence of IBTR is exceptionally low (≤1%) in both arms. Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%. External-beam APBI therefore is a reasonable clinical alternative to WBI for low-risk patients.

Journal of Clinical Oncology
University of Modena and Reggio Emilia (IT), University Medical Center Groningen (NL), University of Antwerp (BE), University of Groningen (NL), University of Trento (IT), Casa Sollievo della Sofferenza (IT), Maastricht University Medical Centre (NL), Medisch Spectrum Twente (NL), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT), Azienda Ospedaliero-Universitaria di Modena (IT), Instituut Verbeeten (NL), Iridium Kankernetwerk (BE), Radiotherapiegroep (NL), Ospedale Bellaria (IT), Maastro Clinic (NL), Istituto Oncologico della Svizzera Italiana (CH)
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon